drugset / Trial / NCT06745128

Tirzepatide for Obesity and Meth Use Disorder

NCT06745128

Phase 2 Active not recruiting 45 enrolled University of Texas Southwestern Medical Center
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label pilot study to evaluate the feasibility and preliminary efficacy of using tirzepatide when prescribed for its United States (US) Food and Drug Administration (FDA)-approved weight-related indication in individuals with comorbid methamphetamine use disorder.

Timeline

Start
2025-02-03
Primary completion
2026-03-31
Completion
2026-03-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide 5 mg Subcutaneous
Subject Tirzepatide Peptide 10 mg Subcutaneous
Subject Tirzepatide Peptide 15 mg Subcutaneous